Search results for "Cardiology"

showing 10 items of 6064 documents

Multicenter and all-comers validation of a score to select patients for manual thrombectomy, the DDTA score.

2021

Background Routine manual thrombectomy (MT) is not recommended in primary percutaneous coronary intervention (P-PCI) but it is performed in many procedures. The objective of our study was validating the DDTA score, designed for selecting patients who benefit most from MT. Methods Observational and multicenter study of all consecutive patients undergoing P-PCI in five institutions. Results were compared with the design cohort and the performance of the DDTA was analyzed in all patients. Primary end-point of the analyses was TIMI 3 after MT; secondary endpoints were final TIMI 3, no-reflow incidence, in-hospital mortality and in-hospital major cardiovascular events (MACE). In-hospital prognos…

medicine.medical_specialtymedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicinecardiovascular diseasesEdetic AcidThrombectomyPrimary angioplastyFramingham Risk Scorebusiness.industryIncidence (epidemiology)Percutaneous coronary interventionGeneral MedicineTreatment OutcomeMulticenter studyCohortCardiology and Cardiovascular MedicinebusinessTIMIMace
researchProduct

No difference in 30-day outcome and quality of life in transradial versus transfemoral access – results from the German Austrian ABSORB registry (GAB…

2021

Abstract Background Radial (RA) instead of femoral access (FA) for coronary interventions has become a European Society of Cardiology Class-IA guideline recommendation. But when the decision on the access site is left to the discretion of the operator, differences in adverse event rates mitigate. Methods We compared the 30-day outcome for RA and FA in all patients recruited for the observational German Austrian ABSORB Registry (GABI-R) in regard to all-cause mortality, stroke, myocardial infarction (MI), TIMI major bleedings (TMB) and quality of life (QoL). All patients were treated with a bioresorbable vascular scaffold. Access site was left to the discretion of the operator. Results In to…

medicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionHemorrhagePercutaneous Coronary InterventionQuality of lifemedicineHumansMyocardial infarctionRegistriesStrokebusiness.industryPercutaneous coronary interventionGeneral MedicineGuidelinemedicine.diseaseFemoral ArteryStrokeTreatment OutcomeAustriaEmergency medicineCohortConventional PCIRadial ArteryQuality of LifeCardiology and Cardiovascular MedicinebusinessTIMI
researchProduct

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability …

2012

Background Although significant efforts have been made to improve ST-segment elevation myocardial infarction (STEMI) outcomes by reducing symptom-onset-to-reperfusion times, strategies to decrease the clinical impact of ischemic reperfusion injury have demonstrated limited success. Bendavia, an intravenously administered mitochondrial targeting peptide, has been shown to reduce myocardial infarct size and attenuate coronary no-reflow in experimental modelswhen given before reperfusion. Design The EMBRACE STEMI study is a phase 2a, randomized, double-blind, placebo-controlled trial enrolling 300 patients with a first-time anterior STEMI and an occluded proximal or mid–left anterior descendin…

medicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionPlacebo-controlled studyMyocardial Reperfusion InjuryPlaceboClinical Trials Phase II as TopicInternal medicinemedicineClinical endpointHumansInfusions Intra-ArterialST segmentcardiovascular diseasesMyocardial infarctionRandomized Controlled Trials as Topicbusiness.industryPatient SelectionPercutaneous coronary interventionmedicine.diseaseResearch DesignConventional PCICardiologyNo-Reflow PhenomenonStentsCardiology and Cardiovascular MedicinebusinessOligopeptidesReperfusion injuryAmerican Heart Journal
researchProduct

The European multicenter cohort study on cyanoacrylate embolization of refluxing great saphenous veins

2014

ObjectiveCyanoacrylate (CA) embolization of refluxing great saphenous veins (GSVs) has been previously described. The outcomes from a multicenter study are still lacking.MethodsA prospective multicenter study was conducted in seven centers in four European countries to abolish GSV reflux by endovenous CA embolization. Neither tumescent anesthesia nor postinterventional compression stockings were used. Varicose tributaries remained untreated until at least 3 months after the index treatment. Clinical examination, quality of life assessment, and duplex ultrasound evaluation were performed at 2 days and after 1, 3, 6, and 12 months.ResultsIn 70 patients, of whom 68 (97.1%) were available for 1…

medicine.medical_specialtymedicine.medical_treatmentPhysical examinationCompression stockingslaw.inventionCohort StudieslawVaricose veinsHumansMedicineSaphenous VeinCyanoacrylatesProspective StudiesEmbolizationProspective cohort studyTumescent anesthesiamedicine.diagnostic_testbusiness.industryRefluxEmbolization TherapeuticSurgeryEuropeTreatment OutcomeVenous InsufficiencyCyanoacrylateAnesthesiaQuality of LifeSurgerymedicine.symptomCardiology and Cardiovascular MedicinebusinessJournal of Vascular Surgery: Venous and Lymphatic Disorders
researchProduct

The QRS narrowing index for easy and early identification of responder to cardiac resynchronization therapy.

2013

The rationale for cardiac resynchronization therapy (CRT) in patients with heart failure (HF) is based on the possibility of inducing substantial left ventricular reverse remodeling. It is well known that some of these patients don't benefit from this therapy (the so-called non-responders) [1,2]. No better predictors of a positive answer to CRT than pre-CRT QRS duration (QRSd) were found [3,4]. The aim of our study was to identify a parameter for an easy and early identification of responders to CRT. In this regard, according to Rickard et al., we identified and observed QRS index (QI), as an expression of electrical remodeling after CRT, and its relation with anatomic reverse remodeling, e…

medicine.medical_specialtymedicine.medical_treatmentPopulationCardiac resynchronization therapyCardiac Resynchronization TherapyElectrocardiographyQRS complexPredictive Value of TestsInternal medicinemedicineHumanscardiovascular diseaseseducationHeart Failureeducation.field_of_studyIschemic cardiomyopathyEjection fractionVentricular RemodelingLeft bundle branch blockbusiness.industryAtrial fibrillationRight bundle branch blockmedicine.diseaseCardiac resynchronization therapy Heart failure ResponderTreatment OutcomeMultivariate Analysiscardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiology
researchProduct

Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardio…

2021

Abstract Aims In breast cancer (BC) patients treated with anthracyclines-based therapies, we aim at assessing whether adjuvant drugs impact cardiac function differently and whether their cardiotoxicity has a regional pattern. Methods and results In a multicentre study, 146 BC patients (56 ± 11 years) were prospectively enrolled and divided into three groups according to the received treatments: AC/EC-Group (doxorubicin or epirubicin + cyclophosphamide), AC/EC/Tax-Group (AC/EC + taxanes), FEC/Tax-Group (fluorouracil + EC + taxanes). Fifty-six patients of the total cohort also received trastuzumab. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were calculated …

medicine.medical_specialtymedicine.medical_treatmentPopulationCardiologyBreast NeoplasmsAnthracyclineAnthracyclines; Breast cancer; Cardiotoxicity; Myocardial strain030204 cardiovascular system & hematologyAnthracyclines Breast cancer Breast Neoplasms Cardiology Cardiotoxicity Echocardiography Female Humans italy Myocardial strain Pharmaceutical Preparations Stroke Volume Trastuzumab Ventricular Function Left Ventricular Dysfunction LeftVentricular Function LeftVentricular Dysfunction Left03 medical and health sciencesBreast cancer0302 clinical medicineTrastuzumabInternal medicineHumansMedicineAnthracyclinesRadiology Nuclear Medicine and imagingeducationeducation.field_of_studyChemotherapyCardiotoxicityEjection fractionbusiness.industryStroke VolumeGeneral MedicineTrastuzumabMyocardial strainChemotherapy regimenCardiotoxicityItalyPharmaceutical PreparationsEchocardiographyFluorouracil030220 oncology & carcinogenesisCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEpirubicinEuropean Heart Journal - Cardiovascular Imaging
researchProduct

Dilation of the ductus venosus by stent implantation increases placental blood perfusion in fetal sheep.

2006

The reduction of resistance to flow in the ductus venous (DV) and a decrease of blood supply to the liver serve for the survival of the fetus during hypoxia. The present study investigated the influence of the increased diameter of the DV on placental blood perfusion.In 15 ewes with twin pregnancies at gestational ages of 117 +/- 4 days, a stent (4 or 5 mm) was placed into the DV of 1 twin (DV(stent) group) under ultrasound guidance. Blood flow rates in the umbilical vein (UV) and DV of both fetuses were measured using Doppler ultrasound. Eight pairs of twin fetuses were included for the final analysis.The dilatation of the DV increased the blood flow volume rate passed through the DV from …

medicine.medical_specialtymedicine.medical_treatmentPulsatile flowGestational AgeHepatic VeinsFetal HypoxiaSensitivity and SpecificityUmbilical veinRandom AllocationPregnancyInternal medicinemedicineAnimalsPlacental CirculationProbabilityFetusSheepbusiness.industryFetoscopyObstetrics and GynecologyStentBlood flowSurgeryDisease Models Animalmedicine.anatomical_structureLiverUltrasonography Doppler PulsedPulsatile FlowCardiologyVascular resistancePregnancy AnimalFemaleStentsVascular ResistancebusinessPerfusionDuctus venosusAmerican journal of obstetrics and gynecology
researchProduct

Residual coronary stenosis after thrombolysis with rt-PA or streptokinase: acute results and 3 weeks follow-up

1987

Ninety-one patients with acute myocardial infarction were assigned to intravenous treatment with streptokinase or rt-PA as part of the randomized trial carried out by the European Study Group for Recombinant Tissue-Type Plasminogen Activator (rt-PA). A patent coronary artery was found in 37 of 45 (82%) patients treated with rt-PA and in 27 of 46 (59%) patients treated with streptokinase 75-90 minutes after start of infusion. Patients were subsequently anticoagulated with heparin or dicoumarol up to a repeat angiography 3 weeks after the infarction. Of the 64 patients with successful reperfusion, 3 died and 3 suffered reocclusion of the vessel. Quantitative analysis of the coronary stenosis …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseInfarctionCoronary DiseaseCoronary AngiographyRandom AllocationReperfusion therapyRecurrenceInternal medicineHumansMedicineStreptokinaseMyocardial infarctionVascular PatencyClinical Trials as Topicmedicine.diagnostic_testbusiness.industryHeparinThrombolysisMiddle Agedmedicine.diseaseRecombinant Proteinsmedicine.anatomical_structureTissue Plasminogen ActivatorAngiographyCardiologyCineangiographyRadiographic Image Interpretation Computer-AssistedCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugArteryEuropean Heart Journal
researchProduct

Thrombolytic therapy for submassive pulmonary embolism.

2012

Approximately 10% of all patients with acute pulmonary embolism (PE) die within the first three months after diagnosis. However, PE is not universally life-threatening, but covers a wide spectrum of clinical severity and death risk. Thrombolytic treatment is indicated patients with acute massive PE who are at high risk for early death, i.e. those patients who present with arterial hypotension and shock. On the other hand, low molecular-weight heparin or fondaparinux is adequate treatment for most normotensive patients with PE. Recombinant tissue plasminogen activator, given as 100 mg infusion over 2 h, is the treatment of choice for patients with PE, although older regimens using urokinase …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseVentricular Dysfunction RightClinical Biochemistry030204 cardiovascular system & hematologyFondaparinuxlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawPolysaccharidesRisk FactorsInternal medicinemedicineHumansStreptokinaseThrombolytic Therapy030212 general & internal medicineIntensive care medicineUrokinaseClinical Trials as Topicbusiness.industryHeparinThrombolysisHeparin Low-Molecular-Weightmedicine.diseaseUrokinase-Type Plasminogen ActivatorTroponin3. Good healthPulmonary embolismRadiographyOncologyFondaparinuxTissue Plasminogen ActivatorAcute DiseaseCardiologybusinessPulmonary EmbolismBiomarkersmedicine.drugCohort studyBest practiceresearch. Clinical haematology
researchProduct

Transcatheter embolization of the kidney with butyl-2-cyanoacrylate: Experimental and clinical results

1978

The technique and efficacy of therapeutic catheter embolization of the kidney with butyl-2-cyanoacrylate (Histoacryl) were studied in 80 rabbits (including control groups) and in 10 dogs. A mixture of butyl-2-cyanoacrylate, 50% glucose, and tantalum powder was used for the embolization. Complete and permanent vascular occlusion was found in nearly all cases. The main complication observed was a reflux of embolizing material into the lumbar arteries, which occurred in seven rabbits. Clinically, therapeutic embolization was performed in six patients with hypernephroma. The indication for embolization in these patients, as well as in two others with iatrogenic lesions, was pronounced hematuria…

medicine.medical_specialtymedicine.medical_treatmentTantalumAdenocarcinomaVascular occlusionCatheterizationlaw.inventionDogsRenal Arterylawmedicine.arterymedicineAnimalsHumansRadiology Nuclear Medicine and imagingCyanoacrylatesEmbolizationHematuriaKidneybusiness.industryLumbosacral RegionRefluxEnbucrilateEmbolization TherapeuticKidney NeoplasmsSurgeryRadiographyCathetermedicine.anatomical_structureCyanoacrylateRabbitsRadiologymedicine.symptomCardiology and Cardiovascular MedicineComplicationbusinessLumbar arteriesCardiovascular Radiology
researchProduct